scholarly journals Potential Role of Oxidative Stress in Ocular Surface Inflammation and Dry Eye Disease

2018 ◽  
Vol 59 (14) ◽  
pp. DES163 ◽  
Author(s):  
Murat Dogru ◽  
Takashi Kojima ◽  
Cem Simsek ◽  
Kazuo Tsubota
Keyword(s):  
Oxidative Stress ◽  
Dry Eye ◽  
Ocular Surface ◽  
Potential Role ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Surface Inflammation ◽  
Ocular Surface Inflammation

scholarly journals One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease

2017 ◽  
Vol 27 (6) ◽  
pp. 678-685 ◽  
Author(s):  
Christophe Baudouin ◽  
Maite Sainz de la Maza ◽  
Mourad Amrane ◽  
Jean-Sébastien Garrigue ◽  
Dahlia Ismail ◽  
...  
Keyword(s):  
Dry Eye ◽  
Cyclosporine A ◽  
Ocular Surface ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Efficacy And Safety ◽  
Open Label ◽  
Once Daily ◽  
Surface Inflammation ◽  
Ocular Surface Inflammation

Purpose The SANSIKA study evaluated the efficacy/safety of 0.1% (1 mg/mL) cyclosporine A cationic emulsion (CsA CE) for treating dry eye disease (DED) with severe keratitis. The double-masked phase demonstrated that CsA CE was effective in reducing corneal damage and ocular surface inflammation, and was well-tolerated over 6 months. Here we report efficacy and safety findings of SANSIKA's open-label extension (OLE). Methods In this multicenter, double-masked, phase III study, patients with severe DED (corneal fluorescein staining [CFS] grade 4, modified Oxford scale) were randomized to once-daily CsA CE (Ikervis®) or its vehicle for 6 months, followed by 6-month open-label, once-daily CsA CE (CsA CE/CsA CE and vehicle/CsA CE groups). Results A total of 177 patients completed the OLE. Efficacy results reiterated the double-masked phase: CsA CE reduced CFS score and human leukocyte antigen-antigen D related expression, improved corneal clearing, and produced continuous improvements in global symptom scores (ocular surface disease index [OSDI], visual analogue scale). The CFS-OSDI response rates (≥2 CFS points, ≥30% OSDI improvement vs baseline) at 12 vs 6 months were 39.1% vs 28.6%, respectively, for CsA CE/CsA CE and 38.0% vs 23.1% for vehicle/CsA CE. Cyclosporine A CE's safety profile was similar to the initial 6 months. The most common treatment-related treatment-emergent adverse event was instillation site pain (7.8%, CsA CE/CsA CE group; 19.0%, vehicle/CsA CE group). No unexpected safety signals were observed; systemic CsA levels were undetectable/negligible in all patients except 2 previously treated with systemic CsA. Conclusions In this 12-month study, once-daily CsA CE was well-tolerated and showed reductions in ocular surface inflammation and improvements in signs/symptoms in DED patients with severe keratitis.

scholarly journals The Protective Effect of Polyunsaturated Fatty Acids against Dry Eye Disease: A Literature Review

2021 ◽  
Vol 11 (10) ◽  
pp. 4519
Author(s):  
Joon-Young Hyon ◽  
Sang-Beom Han
Keyword(s):  
Fatty Acids ◽  
Polyunsaturated Fatty Acids ◽  
Dry Eye ◽  
Ocular Surface ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Common Disease ◽  
Anti Inflammatory ◽  
Surface Inflammation ◽  
Ocular Surface Inflammation

Dry eye disease (DED) is a common disease, and have an adverse effect the physical, functional, and psychological quality of life. It is a multifactorial disorder characterized by the loss of tear film homeostasis, in which self-perpetuating vicious cycle leads to deterioration of function and inflammation of the lacrimal functional unit. Hence, treatment strategies should be aimed at the interruption of the vicious inflammatory cycle and alleviation of ocular surface inflammation. Anti-inflammatory therapies have been shown to improve the signs and symptoms of the disease. Evidence indicates that polyunsaturated fatty acids (PUFAs) may contribute to reinforcement of innate anti-inflammatory mechanisms, and systemic and topical administration of PUFAs may help modulate ocular surface inflammation. In the present review, the authors will introduce the results of clinical and experimental studies to elucidate the mechanism, efficacy, and safety of systemic and topical supplementation with PUFAs as an alternative therapeutic strategy for DED. This review will also include discussion regarding current perspectives, including evidence-based recommendations and possible side effects of PUFAs supplementation. The review of the literature suggests that PUFAs supplementation can be a viable option for the treatment of DED, although further studies are needed for establishment of treatment guidelines.

scholarly journals The closed eye harbors a unique microbiome in dry eye disease

2020 ◽  
Author(s):  
Kent A. Willis ◽  
Cameron K. Postnikoff ◽  
Amelia B. Freeman ◽  
Gabriel Rezonzew ◽  
Kelly K. Nichols ◽  
...  
Keyword(s):  
Dry Eye ◽  
Ocular Surface ◽  
Experimental Models ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Disease Development ◽  
T Helper ◽  
Serial Samples ◽  
Surface Inflammation ◽  
Ocular Surface Inflammation

Dry eye affects millions of individuals. In experimental models, dry eye disease is associated with T helper cell 17-mediated inflammation of the ocular surface that may cause persistent damage to the corneal epithelium. However, the initiating and perpetuating factors associated with chronic inflammation of the ocular surface remain unclear. The ocular microbiota alters ocular surface inflammation and may influence dry eye disease development and progression. Here, we collected serial samples of closed eye tears during a randomized clinical trial of a non-pharmaceutical dry eye therapy and used 16S rRNA metabarcoding to characterize the microbiome. We show the closed dry eye microbiome is distinct from the healthy closed eye microbiome. The ocular microbiome was described only recently, and this report implicates a distinct microbiome in ocular disease development. Our findings suggest an interplay between microbial commensals and inflammation on the ocular surface. This information may inform future studies of the pathophysiological mechanisms of dry eye disease.

Is there a role for tapered topical dose steroidal treatment for dry eye disease? A randomized, pilot study

2021 ◽  
pp. 112067212110487
Author(s):  
Stefano Barabino ◽  
Elisa Montaldo ◽  
Maria Cristina Mingari ◽  
Cosimo Mazzotta ◽  
Sebastiano Giuffrida ◽  
...  
Keyword(s):  
Dry Eye ◽  
Ocular Surface ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Loteprednol Etabonate ◽  
Hla Dr ◽  
Eye Symptoms ◽  
Conjunctival Cells ◽  
Surface Inflammation ◽  
Ocular Surface Inflammation

Purpose: To evaluate the effect of tapered doses of loteprednol-etabonate in dry eye disease patients. Materials and methods: Dry eye and treatment outcomes were assessed by Schirmer I test, tear BUT, lissamine green conjunctival staining, fluorescein corneal staining, and HLA-DR expression on conjunctival cells. Patients received either loteprednol-etabonate 0.5% twice daily for 14 days tapered to once daily for 14 days, and then twice weekly for 28 days ( n = 10), or NaCl 0.9%. Results: A significant decrease of ocular surface inflammation and improvement of symptoms was recorded in the study group compared with controls at days 14 and 56. Change from baseline in HLA-DR expression in CD45+ conjunctival cells was significantly higher in treated patients at day 14. Intraocular pressure and best corrected visual acuity were preserved in all treated eyes. Conclusions: Tapered doses of loteprednol etabonate 0.5% suspension controlled ocular surface inflammation, improving dry eye symptoms.

Corneal lymphangiogenesis facilitates ocular surface inflammation and cell trafficking in dry eye disease

2018 ◽  
Vol 16 (3) ◽  
pp. 306-313 ◽  
Author(s):  
Yong Woo Ji ◽  
Jae Lim Lee ◽  
Hyun Goo Kang ◽  
Nayeong Gu ◽  
Haewon Byun ◽  
...  
Keyword(s):  
Dry Eye ◽  
Ocular Surface ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Cell Trafficking ◽  
Corneal Lymphangiogenesis ◽  
Surface Inflammation ◽  
Ocular Surface Inflammation

The Role of Oxidative Stress and Inflammation in Dry Eye Disease

Cornea ◽  
2009 ◽  
Vol 28 (Suppl 1) ◽  
pp. S70-S74 ◽  
Author(s):  
Murat Dogru ◽  
Tais Wakamatsu ◽  
Takashi Kojima ◽  
Yukihiro Matsumoto ◽  
Tetsuya Kawakita ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Dry Eye ◽  
Dry Eye Disease ◽  
Eye Disease
Sign in / Sign up

Export Citation Format

Share Document